+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Cancer Edition - The Views of 520 Cancer Patient Groups

  • Report

  • 64 Pages
  • May 2022
  • Region: Global
  • PatientView
  • ID: 5342773

The ‘Corporate Reputation of Pharma’ survey - cancer edition, now in its 9th year, and two years into the Covid-19 pandemic. Between November 2021-February 2022, the survey collected the opinions of 520 cancer patient groups on the performance of the pharmaceutical industry during 2021.

Patient groups responding to the ‘Corporate Reputation of Pharma’ survey are uniquely positioned to comment on the pharma industry’s performance during the pandemic. Patient groups not only understand the perceptions of patients, but are also the only healthcare stakeholder to network with all other stakeholders in the healthcare system.

The report provides highlights on:   

  • How the analyst measures pharma’s corporate reputation from a patient perspective; 
  • The headline results of the 2021 survey, from the perspective of cancer patient groups; 
  • The companies included in the 2021 cancer analysis; and 
  • The profiles of 2021’s respondent cancer patient groups. 

SUMMARY OF RESULTS 

FINDINGS AT INDUSTRY LEVEL 
The 520 cancer patient groups responding to the 2021 ‘Corporate Reputation’ survey rated the pharma industry more favourably for corporate reputation than their predecessors in all previous years. 67% of 2021’s respondent cancer patient groups stated that the industry had an “Excellent” or “Good” corporate reputation, against 57% saying the same in 2020. Although many patients with cancer suffered from the indirect consequences of the pandemic, the sentiment of cancer patient groups towards industry, and to its achievements-particularly in relation to the Covid-19 pandemic-remained positive during 2020 and 2021. 81% of 2021’s 520 respondent cancer patient groups thought the pharma industry “Very effective” or “Effective” at supporting patients during the Covid-19 pandemic-higher than the equivalent figures received from 2021’s respondent patient groups of other therapy areas.

However, 2021’s respondent cancer patient groups are not uniform in their views about the pharma industry’s reputation. Lung-cancer patient groups were the most positive about the pharma industry in 2021; blood, digestive, and rare-cancer patient groups were the least positive. So, why the difference? 

Cancer patient groups which marked pharma down for its reputation in 2021 pointed to many unmet areas of patient need in cancer R&D, including: 

  • Patient access to cancer medicines.
  • The need to emphasise the quality of life of patients with cancer.
  • The need for real-world evidence (RWE) on the tolerability and side effects of cancer medicines.
  • The need for cancer R&D to consider larger patient populations. 

COMPANY RANKINGS - ALL CANCERS 

  • The top-three pharma companies out of 30 companies, ranked for their overall corporate reputation in 2021, assessed by respondent cancer patient groups familiar with the company: Pfizer, 1st - Roche/Genentech, 2nd - Novartis, 3rd.
  • The top-three pharma companies out of 26 companies, ranked for their overall corporate reputation in 2021, assessed by respondent cancer patient groups working with the company: Pfizer, 1st - Roche/Genentech, 2nd - Janssen, 3rd. 

Who Should Read this Report? 

Customer Types (Organisations)

  • Pharma companies
  • Biopharma companies
    • Regulatory authorities (e.g EMA, FDA) 
    • NGOs and health charities (usually FOC) including Patient Groups
    • Research and academia

Job Titles/Functions for Pharma and Biopharma Organisations

Core: 

  • Patient Relations
  • Corporate Reputation
  • Public Affairs
  • Professional Affairs
  • Patient Advocacy
  • Communications
  • Market Research

Secondary: 

  • R&D
  • Health economics
  • Outcomes Research
  • Medical Affairs
  • Marketing
  • Brand teams
  • Market Access 
  • Regulatory

Table of Contents

  • Executive summary
  • Cancer patient-group relationships with pharma, 2021
  • Industry-wide findings, 2021
  • Rankings of 30 pharma companies, 2021 v. 2020, as assessed by respondent cancer patient groups familiar with the companies
  • Rankings of 26 pharma companies, 2021 v. 2020, as assessed by respondent cancer patient groups working with the companies
  • Rankings of 13 ‘big-pharma’ companies, 2021 v. 2020, as assessed by respondent cancer patient groups familiar with the companies
  • Rankings of 13 ‘big-pharma’ companies, 2021 v. 2020, as assessed by respondent cancer patient groups working with the companies
  • Rankings of 5 generic pharma companies, 2021 v. 2020, as assessed by respondent cancer patient groups familiar with the companies
  • Profiles of the 30 companies, 2021 (v. 2020)
Appendices
I. Profiles of respondent cancer patient groups, 2021
II. List of respondent cancer patient groups that wished to be attributed, 2021
III. Commentaries and feedback from respondent cancer patient groups on how pharma can improve, 2021-2022
IV. The views of 84 blood-cancer patient groups Supplement
V. The views of 92 breast- and women’s-cancer patient groups Supplement
VI. The views of 28 lung-cancer patient groups Supplement
VII. The views of 42 prostate- and men’s-cancer patient groups Supplement

Tables and Charts
  • The ten indicators measuring corporate reputation, 2021
  • The corporate reputation of the pharmaceutical industry over time, 2013 - 2021, as assessed by cancer patient groups
  • Percentage of respondent patient groups from different therapy areas believing the pharma industry to be “Very effective” or “Effective” at supporting patients during the Covid - 19 pandemic, 2021 v. 2020
  • The corporate reputation of pharma, 2021 - according to patient groups specialising in different cancers
  • Pharma’s response to Covid - 19, 2021 - according to patient groups specialising in different cancers
  • Companies making the biggest rises in the rankings, 2020 to 2021
  • Respondent cancer patient groups, 2021: familiarity, and partnerships, with pharma companies
  • The types of relationships that respondent cancer patient groups have with pharma companies, 2021
  • The corporate reputation of the pharmaceutical industry, 2021 v. 2020 - compared with that of other healthcare sectors - as assessed by cancer patient groups
  • The corporate reputation of the pharmaceutical industry over time, 2013 - 2021 - as assessed by cancer patient groups
  • How good or bad the pharmaceutical industry was in 2021 v. 2020 at carrying
  • out specific activities important to cancer patients and patient groups
  • Percentage of respondent cancer patient groups which thought the pharma industry “Very effective” or “Effective” at supporting patents during the Covid - 19 pandemic, 2021 v. 2020
  • How good or bad the pharmaceutical industry was over time at carrying out specific activities important to cancer patients and patient groups, 2013 - 2021
  • The rankings of 30 pharma companies, 2021 v. 2020 - according to respondent cancer patient groups familiar with the company
  • The rankings of 26 pharma companies, 2021 v. 2020 - according to respondent cancer patient groups working with the company
  • Rankings of 13 ‘big - pharma’ companies, 2021 (v. 2020) - according to
  • respondent cancer patient groups familiar with the companies
  • Rankings of 13 ‘big - pharma’ companies, 2021 (v. 2020) - according to respondent cancer patient groups working with the companies
  • Rankings of 5 generic pharma companies, 2021 (v. 2020) - according to respondent cancer patient groups familiar with the companies
Profiles of the 30 companies, 2021 v. 2020
Each company is profiled by the following measures:
  • The number of respondent cancer patient groups familiar, and working, with the company, 2021.
  • The profile of the respondent cancer patient groups familiar with the company (the number of patients reached; country headquarters; specialities; and geographic remit), 2021.
  • The types of relationships that the company had with its respondent cancer patientgroup partners, 2021.
  • Company performance at the individual indicators of corporate reputation in 2021 - as assessed by respondent cancer patient groups familiar, and working, with the company.
  • Competitors’ relationships in 2021 with the company’s respondent cancer patient - group partners.
  • Overall rankings for the company - as assessed by respondent cancer patient groups familiar, and working, with the company, 2021 v. 2020.
  • Company rankings for each of the indicators of corporate reputation - as assessed by respondent cancer patient groups familiar, and working, with the company, 2021 v.2020
  • Snapshot view: where the company sits in the corporate tiers for each of the indicators(in the higher, the middle, or the lower tier) - as assessed by respondent cancer patient groups familiar, and working, with the company, 2021.
  • Overall rankings of the company, 2015 - 2021 - expressed on the Patient Corporate Reputation Index (PCRI), a measure designed to standardise PatientView’s ranking data
  • (preventing results being skewed by the differing numbers of companies included in the cancer historic analyses over the various years). PCRI ranking is from 0 to 1, with 1 being the best (the highest rank) - as assessed by respondent cancer patient groups familiar with the company.
Profiles of the 30 companies, 2021
  • AbbVie
  • Amgen
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Daiichi Sankyo
  • Dr Reddy’s
  • Eisai
  • Eli Lilly
  • Gilead Sciences
  • GSK
  • Ipsen
  • Janssen
  • Menarini
  • Merck & Co/MSD
  • Merck KGaA/EMD Serono
  • Mylan
  • Novartis
  • Otsuka
  • Pfizer
  • Pierre Fabre
  • Roche/Genentech
  • Sandoz
  • Sanofi
  • Servier
  • Sun Pharma
  • Takeda
  • Teva

Samples

Loading
LOADING...

Companies Mentioned

  • AbbVie 
  • Amgen 
  • Astellas Pharma 
  • AstraZeneca 
  • Bayer 
  • Boehringer Ingelheim 
  • Bristol Myers Squibb 
  • Daiichi Sankyo 
  • Dr Reddy’s 
  • Eisai 
  • Eli Lilly 
  • Gilead Sciences 
  • GSK 
  • Ipsen 
  • Janssen 
  • Menarini 
  • Merck & Co/MSD 
  • Merck KGaA/EMD Serono 
  • Mylan 
  • Novartis 
  • Otsuka 
  • Pfizer 
  • Pierre Fabre 
  • Roche/Genentech 
  • Sandoz 
  • Sanofi 
  • Servier 
  • Sun Pharma 
  • Takeda 
  • Teva 

Methodology

Loading
LOADING...